FDA Commissioner Scott Gottlieb, MD, calls on social media sites and internet providers to crack down on illegal online opioid sales; Ohio will require pharmacy benefit managers and insurers to inform patients of the lowest price for a drug; a court is weighing if a hospital is responsible for a discharged patient with schizophrenia who committed murder.
FDA Commissioner Scott Gottlieb, MD, has called on social media sites and internet providers to help curb illegal sales of opioids. According to The Hill, he believes these entities could be doing more to find and put an end to these illegal sales on their platforms. The FDA wants to bring together CEOs and internet stakeholders to find gaps and solutions to reduce the availability of opioids online.
As part of a push to ensure insured consumers don’t end up paying more for a drug than those without insurance, the Ohio Department of Insurance is going to require insurers and pharmacy benefit managers to disclose the lowest price for a drug. The state will also ban the practice that prohibits pharmacists from discussing when low-cost options are available, reported Reuters. There are similar moves happening at the federal level with 2 bills—the Patient Right to Know Drug Prices Act and the Know the Lowest Price Act of 2018—aimed at preventing “gag clauses.”
Massachusetts’ highest court is weighing whether a hospital should be responsible for a former patient who committed a crime. The New York Times reported that a hospital had released a patient diagnosed with schizophrenia and court ordered to be held for up to 6 months after just 11 days at the hospital. Within weeks of his release, he had killed a neighbor. The plaintiffs’ attorneys allege that the patient was clearly still dangerous when he was discharged and that the hospital is at fault for violating the court order to release him early.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen